Madrigal (MDGL) delivered earnings and revenue surprises of 34.22% and 1.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price ...

Madrigal Pharmaceuticals Inc. MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter.

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

Below is a chart showing VST's trailing twelve month trading history, with the $150 strike highlighted in orange: Madrigal Pharmaceuticals Inc (Symbol: MDGL) options are showing a volume of 2,291 ...

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Madrigal ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular, metabolic, and liver diseases ...

Short interest in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) decreased during the last reporting period, falling from 4.08M to 3.98M. This put 26.21% of the company's publicly available shares short.